Clinical Trial

Metformin Versus Myo-inositol in the Management of Polycystic Ovarian Disease: A Comparative Study

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated March 10, 2026 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
In polycystic ovary syndrome (PCOS), changes in physical appearance i.e. weight gain, hirsutism, menstrual disturbances and infertility result in reduced quality-of-life. PCOS is one of the most common endocrine disorders affecting about 4% to 8% of women of reproductive age. Diagnosis is primarily clinical with Rotterdam criteria being the most commonly followed criteria, which require the presence of two out of the three criteria including oligo and/or anovulation, clinical and/or biochemical signs of hyperandrogenism and polycystic ovaries on ultrasound. The objective of this study is to compare the outcome of Metformin versus Myo-inositol in the management of polycystic ovarian disease.
Trial Details
NCT Number NCT07459595
Lead Sponsor Fatima Tariq
Conditions Polycystic Ovarian Syndrome (PCOS)
Enrollment 60 participants
Start Date 2026-05-01
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-10